^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
XP-102
i
Other names: XP-102, BI 882370, BI882370, XP102, BI-882370, XP 102
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Boehringer Ingelheim, Xynomic
Drug class:
pan-RAF inhibitor
Related drugs:
10ms
ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • XP-102
2years
ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Initiation date: Jun 2022 --> Dec 2022
Trial initiation date • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • XP-102
over2years
ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc.
New P1/2 trial • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • XP-102
Share via
